Phase II/III study in schizophrenia patients show positive top-line results
Drug Discovery World
MAY 10, 2024
Newron Pharmaceuticals has announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.
Let's personalize your content